Zymeworks Presents Results of the Completed Dose Escalation Portion of the Ongoing Phase 1 Study of ZW25 at the San Antonio Breast Cancer Symposium Continued Clinical Benefit of Single Agent ZW25 in Heavily Pretreated HER2-High Patients
Tuesday, December 5, 2017 1 min read
Key Takeaway: Zymeworks Presents Results of the Completed Dose Escalation Portion of the Ongoing Phase 1 Study of ZW25 at the San Antonio Breast Cancer Symposium Continued Clinical Benefit of Single Agent ZW25 in Heavily Pretreated HER2-High Patients
Full Press Release Details
Zymeworks Presents Results of the Completed Dose Escalation Portion of the Ongoing Phase 1 Study of ZW25 at the San Antonio Breast Cancer Symposium Continued Clinical Benefit of Single Agent ZW25 in Heavily Pretreated HER2-High Patients.